All In Biotech

Drug Trial Radar · NCT07184632

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability and Efficacy of Once-weekly NNC0662-0419 in Participants Living With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

224

Actual

Start

Oct 1, 2025

Primary completion

Dec 14, 2026

Study completion Dec 14, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.

Conditions

  • Overweight
  • Obesity

Interventions

  • NNC0662-0419Drug

    NNC0662-0419 will be administered subcutaneously.

  • PlaceboDrug

    Placebo matched to NNC0662-0419 will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of treatment-emergent adverse events (TEAE)Time frame: From baseline (week 0) to end of study (up to week 44)
  2. Part B: Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 36)
  3. Part C: Occurrence of premature treatment discontinuation (Yes/No)Time frame: At end of treatment (week 24)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion, Phoenix

    Tempe, Arizona

  • Celerion, Lincoln

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.